Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282531 | 0.79 | MAPK1 (0.41) | GPR119GBA1MAPTALDH1A1LMNA | |
| SCHEMBL18282618 | 0.79 | GBA1 (0.41) | TLR9OPRM1OPRD1OGFRL1GBA1 | |
| SCHEMBL20423540 | 0.79 | GBA1 (0.39) | GPR119TLR9OPRM1OPRD1OGFRL1 | |
| SCHEMBL20423972 | 0.78 | USP2 (0.42) | GBA1MAPTALDH1A1LMNAMAP4K4 | |
| SCHEMBL18282608 | 0.78 | SMARCA2 (0.49) | GPR119TLR9GBA1MAPTALDH1A1 | |
| SCHEMBL18282640 | 0.77 | MAPT (0.42) | TLR9OPRM1OPRD1OGFRL1GBA1 | |
| SCHEMBL2384235 | 0.76 | POLB (0.48) | GPR119TLR9GBA1MAPTALDH1A1 | |
| SCHEMBL18282671 | 0.74 | KIT (0.46) | GPR119TLR9OPRM1OPRD1OGFRL1 | |
| SCHEMBL18282513 | 0.74 | GBA1 (0.43) | GPR119TLR9OPRM1OPRD1OGFRL1 | |
| SCHEMBL18282583 | 0.73 | KIT (0.43) | GPR119TLR9GBA1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709316-B | 2- (1-heteroarylpiperazin-4-yl) methyl-1, 4-benzodioxane derivatives as alpha 2C antagonists | 奥赖恩公司 | 2021-08-17 | — | — | CN | disclosed |
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | ORION CORPORATION (FI) | 2020-09-15 | — | — | US | disclosed |
| EP-3303327-B1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORP (FI) | 2020-03-11 | — | — | EP | disclosed |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2019-09-26 | — | — | US | disclosed |
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2018-08-02 | — | — | US | disclosed |
| EP-3303327-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | Orion Corporation (FI) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193551-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215739-A1 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | GPR119 1098/4885TLR9 4304/4885OPRM1 1/4885 |
| US-10774074-B2 | 2-(1-heteroarylpiperazin-4-yl)methyl-1,4-benzodioxane derivatives as alpha2C antagonists | OPRM1, HTR2C, ADRA2C | GPR119 1098/4885TLR9 4304/4885OPRM1 1/4885 |
| US-20190292170-A9 | 2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS | OPRM1, HTR2C, ADRA2C | GPR119 1098/4885TLR9 4304/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.